Abstract: HPLC-DAD-directed isolation and purification of the methanol extract of stems of *Arcangelisia gusanlung* H. S. Lo. led to the isolation of a new protoberberine alkaloid, gusanlung E (1), along with fourteen known derivatives 2–15, seven of which were obtained from the genus *Arcangelisia* for the first time. The structures and absolute stereochemistry of these compounds were elucidated on the basis of spectroscopic analyses, including 1D and 2D NMR, mass spectrometry, and CD analyses. Gusanlung E (1) expressed weak cytotoxic activity against the SGC 7901 cell line with an IC$_{50}$ value of 85.1 µM.

Keywords: protoberberine alkaloid; *Arcangelisia gusanlung*; gusanlung E
1. Introduction

*Arcangelisia gusanlung* H. S. Lo (Menispermaceae) is a small shrub widely distributed in the south of China including the provinces of Guangdong, Guangxi, and Hainan. The stems of *A. gusanlung* have been clinically used in Chinese folk medicine as an anti-inflammatory, antipyretic, and detoxication reagent [1]. Previous phytochemical investigations of the plant revealed the presence of a series of protoberberine alkaloids [2–4] and megastigane glycosides [5] in its stems. Protoberberine alkaloids, which belong to a isoquinoline alkaloid class, are widely distributed in many species of the Berberidaceae, Annonaceae, Fumariaceae, Papaveraeae, Ranunculaceae, Rutaceae, and other plant families, encompassing a diverse class of secondary metabolites with many pharmacologically active members, such as berberine and palmatine [6,7]. Over the last decade, these alkaloids have attracted considerable attention due to their wide range of biochemical and pharmacological actions, which have applications in various therapeutic areas such as cancer, inflammation, diabetes, depression, hypertension, and various infectious areas [8].

In order to further investigate the active components of *A. gusanlung*, HPLC-DAD-directed isolation was carried out on the CH$_3$OH extract of the stems of *A. gusanlung*. As a result, 15 protoberberine alkaloids including a new one, gusanlung E (1), together with fourteen known derivatives 2–15, seven of which were obtained from the genus *Arcangelisia* for the first time (Figure 1). Herein, we report the detailed isolation and structural characterization of these compounds, as well as cytotoxic activity of gusanlung E (1).

![Figure 1. Structures of compounds 1–15.](image)

2. Results and Discussion

2.1. Structural Characterization

Gusanlung E (1) was obtained as yellow crystals, and its molecular formula was determined as C$_{19}$H$_{22}$NO$_4$ by HR-ESI-MS at $m/z$ 328.1581 [M]$^+$ (calcd. for C$_{19}$H$_{22}$NO$_4$: 328.1549), indicating ten degrees of unsaturation. The $^1$H-, $^{13}$C-NMR and HSQC spectroscopic data suggested the presence of
Molecules 2014, 19

19 carbons. The $^1$H-NMR spectrum showed four aromatic protons at δ 6.86, 6.71, 6.62 and 6.61, one aromatic methoxyl group at δ 3.87 (3H, s) and an N-methyl signal at δ 3.20 (3H, s). The signal at δ 3.26 (2H, m) was assigned as H-5, whereas the signals at 3.49 (1H) and 3.82 (1H) were assigned as germinal protons to H-6. Moreover, signals of a pair of methylene protons and an isolated -CH-CH₂-moiety were found in the aliphatic region. The large coupling constant (15.0 Hz) of a pair of doublets at δ 4.71 and δ 4.52 suggested the existence of germinal protons, which was confirmed by HSQC. This is a typical characteristic of methylene group (C-8) of the protoberberine alkaloids [9]. The signals of an isolated -CH-CH₂-moiety were assigned to C-13a and C-13. In addition, there were three exchangeable protons were observed at δ 9.13 in the proton NMR spectrum of DMSO-$d_6$. Analysis of the $^1$H-, $^{13}$C-, and HSQC NMR spectroscopic data (Table 1) revealed that there were twelve aromatic carbon signals: four aromatic methylene ($\delta_C$:115.8, 114.5, 114.1, 113.3), eight aromatic quaternary (four oxygenated); four methylene; one methane; one aromatic methoxyl ($\delta_C$ 57.6) and one N-methyl carbon ($\delta_C$ 50.7). According to the above information, the structure of 1 was closely related to the 2,3,10,11-tetrasubstituted-N-methyltetrahydroprotoberberine skeleton [10,11]. The complete assignments were accomplished using $^1$H-$^1$H COSY, HSQC, HMBC and NOESY spectra.

Table 1. $^1$H- (600 MHz, δ ppm, $J$ in Hz), $^{13}$C-NMR (150 MHz, δ ppm), COSY and HMBC spectroscopic data for compound 1 in methanol-$d_4$.

| Position | $\delta_C$ | $\delta_H$ ($J$ Hz) | COSY | HMBC |
|----------|------------|---------------------|------|------|
| 1        | 114.5, CH  | 6.71 s              | C-3, C-4a, C-13a |
| 1a       | 125.8, C   |                     |      |      |
| 2        | 147.5, C   |                     |      |      |
| 3        | 150.1, C   |                     |      |      |
| 4        | 113.3, CH  | 6.83 s              | C-2, C-3, C-1a, C-4a, C-5 |
| 4a       | 120.3, C   |                     |      |      |
| 5        | 24.3, CH₂  | 3.28, 3.23 m        | H-6  | C-1a, C-4a, C-4 |
| 6        | 53.3, CH₂  | 3.82, 3.49 m        | H-5  | C-4a, C-13a, N-CH₃, C-8, C-5 |
| 8        | 65.1, CH₂  | 4.71, 4.52 d (15)   |      | C-12a, C-8a, C-6, C-9, C-13a, N-CH₃, C-12a |
| 8a       | 118.0, C   |                     |      |      |
| 9        | 114.1, CH  | 6.60 s              | C-11, C-12a, C-10, C-8a, C-8 |
| 10       | 146.7, C   |                     |      |      |
| 11       | 147.8, C   |                     |      |      |
| 12       | 115.8, CH  | 6.83 s              | C-11, C-10, C-9, C-8a, C-13 |
| 12a      | 122.0, C   |                     |      |      |
| 13       | 35.4, CH₂  | 3.35 dd (4.8, 19.6) 3.02 dd (10.2, 18.0) | H-13a | C-8a, C-1a, C-12, |
| 13a      | 67.6, CH   | 4.66 dd (6.6, 10.2)  | H-13 | C-12a, C-4a, C-1, C-8, C-13 |
| 3-OCH₃   | 56.7, CH₁  | 3.87 s              | C-3, C-4, C-2 |
| N-CH₃    | 50.7, CH₁  | 3.20 s              | C-13a, C-6, C-8 |

Interpretation of the $^1$H-$^1$H COSY NMR data of 1 confirmed that two isolated proton spin-systems belong to C-5-C-5a and C-13-C-13a units, and the remaining connections were established by analysis of HMBC correlations. The HMBC correlations from -OCH₃ to C-1, C-3, and C-4, whereas correlations from H-1 to C-3, C-13a and C-4a, and from H-4 to C-1a, C-2 and C-5, indicated that A ring possessed 2-OH and 3-OCH₃ substitutions (Figure 2). The result was further confirmed by NOESY spectrum, in which the NOE correlations between 3-OCH₃ and H-4, H-4 and H-5, H-1 and H-13a were observed. In the same way, the cross peaks of H-9 with C-8, C-12a, C-11 and H-12 with
C-10, C-8a, C-13 in the HMBC spectrum suggested dihydroxyl substitutions at C-10 and C-11 in D ring. Moreover, H-9 was correlated with H-8 and H-12 with H-13 in the NOESY spectrum (Figure 3). Therefore, the planar structure of 1 was characterized as 2,10,11-trihydroxy-3-methoxy-N-methyltetrahydroprotobberine.

The relative configuration was determined by a NOESY experiment. The N-methyl protons showed a NOE correlation with H-13a (Figure 3). Moreover, the NOE correlation between H-6 and N-methyl protons suggested the axial position of H-6. The H-13 signal showed a large coupling constant (12.0 Hz) with the signal of H-13a, indicating that H-13 was at axial position [11]. Meanwhile, the 1H- and 13C-NMR chemical shifts of N-methyl group (δH 3.20, δC 50.7) as well as a NOESY cross peak between the N-methyl group and H-13a suggested a B/C-cis fused form [12]. Furthermore, the negative value of specific optical rotation and circular dichroism (CD) curve indicated the 7S, 13aS configurations [13]. Accordingly, the structure of the new compound was elucidated as shown in Figure 1.

**Figure 2.** 1H-1H COSY and key HMBC correlations of compound 1.

**Figure 3.** Key NOE of compound 1.

Compounds 2–15 were identified as berberine (2) [14], thalifendine (3) [15], palmatine (4) [16], stephaine (5) [17], 8-oxyberbeine (6) [18], tetrahydropalmatine (7) [19], 8-oxotetrahydroplamatine (8) [20], gusanlung C (9) [7], gusanlung B (10) [6], jatrorrhizine (11) [21], 8,13-dioxo-14-hydroxycanadine (12) [22], 8,13-dioxo-14-methoxycanadine (13) [23,24], corydaline (14) [24] and tetrahydrothalifendine (15) [25], respectively, by comparison of the 1H- and 13C-NMR data with reported spectroscopic data. Among them, 5, 7, 8, and 12–15 were isolated from this plant for the first time.

2.2. Cytotoxic Activities

Gusanlung E (1) exhibited weak cytotoxic activity against cell line SGC 7901 with IC_{50} value of 85.1 µM.
3. Experimental Section

3.1. General Experimental Procedures

Optical rotations were recorded on a JASCO DIP-1000 polarimeter (JASCO, Kyoto, Japan). IR spectra were recorded on a Shimadzu FTIR-8400s (Shimadzu, Kyoto, Japan). UV spectra were run on a Shimadzu UV-2550 UV-VIS spectrophotometer (Shimadzu, Kyoto, Japan). CD spectra were measured on a JASCO J-810 spectrometer (JASCO, Kyoto, Japan). 1D and 2 D NMR spectra were measured in methanol-$d_4$ ($\delta_H$ 3.30/$\delta_C$ 49.5) on a Bruker Avance III 600 spectrometer ($^1$H: 600 MHz, $^{13}$C: 150 MHz) (Munich, Ettlingen, Germany). HRESIMS were obtained using a LTQ Orbitrap XL spectrometer (Thermo Fisher, Bremen, Germany). Analytical HPLC was performed on a Waters 600 with a Waters 2996 photodiode array detector (Waters, Milford, MA, USA). Semipreparative HPLC was performed on a Shimadzu LC-6AD with a Shimadzu SPD-6AD spectrophotometric detector (Shimadzu, Kyoto, Japan).

3.2. Plant Material

The stems of *A. gusanlung* were collected from Wanning City in Hainan Province of The People’s Republic of China in August 2008. The sample was identified by Prof. Guobiao Chen from the Institute for Drug Control of Hainan Province. A voucher specimen (No. 200808) was deposited in the herbarium of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing.

3.3. Extraction and Isolation

The air-dried and smashed stems of *A. gusanlung* (18 kg) were extracted with MeOH (3 × 80 L) and afforded a crude extract of 880 g after evaporation of the solvent under vacuum. The extract was suspended in H$_2$O (2.0 L) and partitioned sequentially with petroleum ether (3 × 3.0 L), EtOAc (3 × 3.0 L), and n-BuOH (3 × 3.0 L). The EtOAc extract (40 g) was subjected to chromatography over silica gel (800 g, 100–200 mesh) and eluted with CH$_2$Cl$_2$–MeOH to yield six fractions (E1 to E6) on the basis of TLC and HPLC-DAD analyses. Repeated crystallization of fraction E5 (CH$_2$Cl$_2$–MeOH) yielded compounds 2 (10 g), 3 (3 g) and 4 (2 g). The n-BuOH extract (630 g) was subjected to column chromatography over macroporous resin D101 and eluted successively with EtOH–H$_2$O (1:9, 3:7, 6:4, and 1:0) to yield four fractions (B1 to B4). Fraction B1 (10 g) was further subjected to column chromatography over macroporous resin AB-8 and eluted successively with EtOH–H$_2$O (1:9, 2:8, 3:7 and 1:0) to yield five fractions (B1-1 to B1-5). Subfraction B1-3 (1.5 g) was subjected to chromatography over silica gel C$_{18}$ (45 g) and eluted with MeOH-Water to yield 1 (50 mg), 14 (7 mg) and 15 (11 mg). Fraction B2 (40 g) was subjected to chromatography over silica gel (400 g, 100–200 mesh) and eluted with CH$_2$Cl$_2$–MeOH to yield 12 fractions (B2-1 to B2-12) on the basis of TLC and HPLC-DAD analyses. Fraction B2-3 (1.0 g) was subjected to chromatography over silica gel (30 g, 200–300 mesh) and eluted with CH$_2$Cl$_2$–MeOH to yield 10 subfractions (B2-3-1 to B2-3-10). Subfractions were further separated on Sephadex LH-20 (MeOH) followed by semipreparative HPLC (35% aq. MeOH) to give compounds 5 (8 mg), 6 (23 mg), 7 (20 mg), 8 (12 mg), 9 (10 mg), 10 (27 mg), 11 (12 mg), 12 (120 mg) and 13 (17 mg).
Gusanlung E (1): yellow crystals; [α]_D^20 −20 (c 0.03, MeOH); UV\text{max} (MeOH) nm 210.0, 287.0; IR\text{max} (KBr): 3179 (OH), 3042, 2361, 1617 (C=O), 1532 cm\textsuperscript{−1}; CD (MeOH) Δε (nm): −9.35 (239), −1.34 (290); \textsuperscript{1}H- and \textsuperscript{13}C-NMR data, see Table 1; HRESIMS m/z 328.1581 [M]+ (calcd for C\textsubscript{19}H\textsubscript{22}NO\textsubscript{4}\textsuperscript{+}, 328.1577).

Berberine (2): yellow crystals; HRESIMS m/z 336.1205 [M]+ (calcd for C\textsubscript{20}H\textsubscript{18}NO\textsubscript{4}+ 336.1236); \textsuperscript{1}H-NMR δ: 3.27 (2H, t, J = 6.0 Hz, H-5), 4.11 (3H, s, 10-OCH\textsubscript{3}), 4.21 (3H, s, 9-OCH\textsubscript{3}), 4.94 (2H, t, J = 6.0 Hz, H-6), 6.11 (2H, s, -OCH\textsubscript{2}O-), 6.97 (1H, s, H-4), 7.67 (1H, s, H-1), 8.01 (1H, d, J = 9.0 Hz, H-12), 8.12 (1H, d, J = 9.0 Hz, H-11), 8.71 (1H, s, H-13), 9.77 (1H, s, H-8); \textsuperscript{13}C-NMR δ: 26.4 (C-5), 55.2 (C-6), 57.1 (10-OCH\textsubscript{3}), 62.0 (9-OCH\textsubscript{3}), 102.1 (-OCH\textsubscript{2}O-), 105.4 (C-1), 108.4 (C-4), 120.1 (C-13), 120.4 (C-1a), 121.4 (C-8a), 123.5 (C-12), 126.7 (C-11), 130.6 (C-4a), 132.9 (C-12a), 137.4 (C-13a), 143.6 (C-9), 145.4 (C-8), 147.6 (C-2), 149.7 (C-3), 150.4 (C-10).

Thalifendine (3): faint yellow powder; HRESIMS m/z 322.1058 [M]+ (calcd for C\textsubscript{19}H\textsubscript{16}NO\textsubscript{4}+ 322.1074); \textsuperscript{1}H-NMR δ: 3.27 (2H, t, J = 6.0 Hz, H-5), 4.16 (3H, s, 9-OCH\textsubscript{3}), 4.90 (2H, t, J = 6.0 Hz, H-6), 6.10 (2H, s, -OCH\textsubscript{2}O-), 6.95 (1H, s, H-4), 7.63 (1H, s, H-1), 7.88 (1H, d, J = 9.0 Hz, H-12), 7.78 (1H, d, J = 9.0 Hz, H-11), 8.64 (1H, s, H-13), 9.77 (1H, s, H-8); \textsuperscript{13}C-NMR δ: 28.3 (C-5), 57.1 (C-6), 62.4 (9-OCH\textsubscript{3}), 103.6 (-OCH\textsubscript{2}O-), 106.4 (C-1), 109.4 (C-4), 121.7 (C-13), 122.0 (C-1a), 124.4 (C-8a), 124.7 (C-12), 132.4 (C-11), 131.6 (C-4a), 135.3 (C-12a), 139.4 (C-13a), 143.2 (C-9), 145.2 (C-8), 150.0 (C-2), 152.1 (C-3), 150.8 (C-10).

Palmatine (4): a faint yellow powder; HRESIMS m/z 352.1547 [M]+ (calcd for C\textsubscript{21}H\textsubscript{22}NO\textsubscript{4}+ 352.1543); \textsuperscript{1}H-NMR δ: 3.29 (2H, t, J = 6.0 Hz, H-5), 3.79 (3H, s, 10-OCH\textsubscript{3}), 3.81 (3H, s, 3-OCH\textsubscript{3}), 3.83 (3H, s, 9-OCH\textsubscript{3}), 3.84 (3H, s, 10-OCH\textsubscript{3}), 4.97 (2H, t, J = 6.0 Hz, H-6), 7.01 (1H, s, H-4), 7.66 (1H, s, H-1), 7.97 (1H, d, J = 9.0 Hz, H-12), 8.10 (1H, d, J = 9.0 Hz, H-11), 8.80 (1H, s, H-13), 9.79 (1H, s, H-8); \textsuperscript{13}C-NMR δ: 27.3 (C-5), 56.6 (C-6), 57.2 (2-OCH\textsubscript{3}), 57.3 (3-OCH\textsubscript{3}), 57.3 (3-OCH\textsubscript{3}), 63.0 (9-OCH\textsubscript{3}), 104.7 (C-1), 110.5 (C-4), 121.5 (C-13), 121.9 (C-1a), 120.1 (C-8a), 124.4 (C-12), 126.9 (C-11), 132.6 (C-4a), 126.9 (C-12a), 138.4 (C-13a), 153.7 (C-9), 145.3 (C-8), 148.9 (C-2), 149.7 (C-3), 144.6 (C-10).

Stephabine (5): faint yellow powder; HRESIMS m/z 368.1486 [M]+ (calcd for C\textsubscript{21}H\textsubscript{22}NO\textsubscript{5}+ 368.1498); \textsuperscript{1}H-NMR δ: 3.24 (2H, t, J = 5.4 Hz, H-5), 3.95 (3H, s, 2-OCH\textsubscript{3}), 3.93 (3H, s, 3-OCH\textsubscript{3}), 3.99 (3H, s, 10-OCH\textsubscript{3}), 4.00 (3H, s, 11-OCH\textsubscript{3}), 4.76 (2H, t, J = 5.4 Hz, H-6), 6.90 (1H, s, H-4), 7.00 (1H, s, H-12), 7.62 (1H, s, H-9), 8.84 (1H, s, H-13), 9.14 (1H, s, H-8).

8-Oxyberberine (6): faint yellow powder; HRESIMS m/z 352.1200 [M+H]\textsuperscript{+} (calcd for C\textsubscript{20}H\textsubscript{17}NO\textsubscript{5} 352.1185); \textsuperscript{1}H-NMR δ: 2.83 (2H, t, J = 6.6 Hz, H-5), 3.78 (3H, s, 10-OCH\textsubscript{3}), 3.84 (3H, s, 9-OCH\textsubscript{3}), 3.89 (2H, t, J = 6.6 Hz, H-6), 6.01 (2H, s, -OCH\textsubscript{2}O-), 6.69 (1H, s, H-4), 6.95 (1H, s, H-1), 6.53 (1H, d, J = 9.0 Hz, H-12), 7.02 (1H, d, J = 9.0 Hz, H-11), 7.35 (1H, s, H-13), 8.03 (1H, s, N-H); \textsuperscript{13}C-NMR δ: 29.8 (C-5), 38.8 (C-6), 56.2 (10-OCH\textsubscript{3}), 60.9 (9-OCH\textsubscript{3}), 102.3 (-OCH\textsubscript{2}O-), 103.6 (C-13), 104.9 (C-1), 109.6 (C-4), 109.7 (C-11), 119.7 (C-13a), 124.6 (C-12), 126.4 (C-8a), 129.8 (C-4a), 134.0 (C-12a), 135.9 (C-1a), 148.1 (C-2), 148.8 (C-3), 149.6 (C-10), 153.0 (C-9), 160.3 (C-8).
Tetrahydropalmatine (7): faint yellow powder; HRESIMS m/z 356.1862 [M+H]^+ (calcd for C21H26NO4 356.1862); ^1H-NMR δ: 2.68 (2H, m, H-5), 2.84 (1H, dd, J13β, 13α = 13.0 Hz, J13β, 13α = 15.0 Hz, H-13α), 3.20 (1H, dd, J13α, 13α = 3.6 Hz, J13α, 13β = 15.6 Hz, H-13β), 3.23 (2H, m, H-6), 3.53 (1H, d, J = 15.6 Hz, H-8α), 3.59 (1H, dd, J13α, 13β = 12.0 Hz, J13α, 13α = 3.6 Hz, H-13a), 3.84 (6H, s, 9-OCH3, 10-OCH3), 3.86 (3H, s, H-2), 3.88 (3H, s, 3-OCH3), 4.26 (1H, d, J = 15.6 Hz, H-8β), 6.61 (1H, s, H-4), 6.75 (1H, s, H-1), 7.70 (1H, d, J = 9.0 Hz, H-11), 7.85 (1H, d, J = 9.0 Hz, H-12).

8-Oxotetrahydropalmatine (8): faint yellow powder; HRESIMS m/z 370.2023 [M+H]^+ (calcd for C21H24NO14 370.1654); ^1H-NMR δ: 2.78 (1H, dd, J13β, 13α = 13.0 Hz, J13β, 13α = 15.0 Hz, H-13β), 2.80 (1H, dd, J13α, 13α = 3.0 Hz, J13α, 13β = 15.0 Hz, H-13α), 2.92 (2H, m, H-5), 3.02 (1H, m, H-6α), 3.90 (9H, s, 3 × OCH3), 4.02 (3H, s, OCH3), 4.70 (1H, m, H-6β), 5.05 (1H, dd, J13α, 13β = 9.0 Hz, J13α, 13α = 2.0 Hz, H-13a), 6.67 (1H, s, H-4), 6.68 (1H, s, H-1), 6.95 (1H, d, J = 9.0 Hz, H-12), 7.00 (1H, d, J = 9.0 Hz, H-11); ^13C-NMR δ: 29.8 (C-5), 38.0 (C-13), 39.2 (C-6), 54.5 (C-13a), 56.2 (3 × OCH3), 61.5 (OCH3), 109.5 (C-1), 111.5 (C-4), 115.5 (C-11), 120.6 (C-12), 123.0 (C-8a), 127.3 (C-12a), 130.7 (C-1a), 147.9 (C-3), 148.0 (C-2), 150.7 (C-10), 153.4 (C-9), 162.7 (C-8).

Gusanlung C (9): faint yellow powder; HRESIMS m/z 314.1395 [M+H]^+ (calcd for C18H20NO4 314.1392); ^1H-NMR δ: 2.70 (2H, t, J = 7.2 Hz, H-5), 3.44 (2H, t, J = 7.2 Hz, H-6), 3.82 (3H, s, COOCH3), 6.46 (1H, d, J = 15.6 Hz, H-13a), 6.70 (2H, d, J = 8.0 Hz, H-9, H-11), 6.79 (1H, d, J = 8.4 Hz, H-4), 6.98 (1H, dd, J = 8.4, 2.0 Hz, H-3), 7.01(2H, d, J = 8.0 Hz, H-8a, H-12), 7.10(1H, d, J = 2.0 Hz, H-1), 7.41 (1H, d, J = 15.6 Hz, H-13), 8.00 (1H, t, J = 7.2 Hz, H-7); ^13C-NMR δ: 36.8 (C-5), 40.2 (C-6), 56.5 (COOCH3), 111.6 (C-13a), 116.0 (C-8a, C-12), 116.1 (C-4), 119.7 (C-1), 122.5 (C-2), 128.0 (C-1a), 130.3 (C-9, C-11), 131.0 (C-4a), 140.7 (C-13), 148.6 (C-12a), 149.0 (C-12), 156.7 (C-2), 167.0 (C-8).

Gusanlung B (10): yellow powder; HRESIMS m/z 353.1252 [M]^+ (calcd for C20H19NO5 353.1263); ^1H-NMR δ: 2.76 (1H, dd, J13β, 13α = 13.0 Hz, J13β, 13α = 15.0 Hz, H-13β), 2.68 (1H, dd, J13α, 13α = 3.0 Hz, J13α, 13β = 15.0 Hz, H-13a), 2.83 (2H, m, H-5), 2.97 (1H, m, H-6α), 3.86 (3H, s, 9-OCH3), 4.01 (3H, s, 10-OCH3), 4.65 (1H, dd, J13α, 13β = 13.0 Hz, J13α, 13α = 3.0 Hz, H-13a), 4.92 (1H, m, H-6β), 5.96 (2H, s, OCH2O), 6.65 (1H, s, H-4), 6.67 (1H, s, H-1), 6.93 (1H, d, J = 9.0 Hz, H-12), 7.02 (1H, d, J = 9.0 Hz, H-11); ^13C-NMR δ: 29.0 (C-5), 38.2 (C-13), 39.2 (C-6), 55.5 (C-13a), 56.2 (9-OCH3), 61.5 (10-OCH3), 101.5 (OCH2O), 106.5 (C-5), 108.5 (C-4), 115.8 (C-11), 121.5 (C-12), 125.9 (C-8a), 128.7 (C-4a), 128.9 (C-12a), 131.0 (C-1a), 146.5 (C-2), 146.6 (C-3), 150.1 (C-10), 154.3 (C-9), 162.4 (C-8).

Jatrorrhizine (11): yellow powder; HRESIMS m/z 338.1396 [M]^+ (calcd for C20H20NO4^+ 338.1392); ^1H-NMR δ: 3.23 (2H, t, J = 6.0 Hz, H-5), 4.04 (3H, s, 2-OCH3), 4.18 (3H, s, 9-OCH3), 4.15 (3H, s, 10-OCH3), 4.95 (2H, t, J = 6.0 Hz, H-6), 7.46 (1H, s, H-4), 7.80 (1H, s, H-1), 8.08 (1H, d, J = 9.0 Hz, H-12), 8.02 (1H, d, J = 9.0 Hz, H-11), 8.81 (1H, s, H-13), 9.70 (1H, s, H-8); ^13C-NMR δ: 26.8 (C-5), 57.2 (C-6), 56.5 (2-OCH3), 62.2 (9-OCH3), 115.5 (C-1), 112.5 (C-4), 119.8 (C-13b), 121.5 (C-13), 122.9 (C-12a), 123.0 (C-12), 123.8 (C-11), 130.3 (C-4a), 135.0 (C-8a), 139.4 (C-13a), 144.6 (C-10), 145.3 (C-8), 148.9 (C-2), 149.9 (C-3), 151.7 (C-9).

8,13-Dixo-14-hydroxycamadine (12): faint yellow powder; HRESIMS m/z 406.0900 [M+Na]^+ (calcd for C26H17NO7Na 406.0903); ^1H-NMR δ: 2.97–3.01 (1H, m, H-5a), 3.51–3.55 (1H, m, H-5b), 3.42 (1H,
m, H-6a), 3.87 (3H, s, 9-OCH3), 3.89 (3H, s, 10-OCH3), 4.15 (1H, m, H-6b), 5.96 (2H, s, -OCH2O-), 6.67 (1H, s, H-4), 6.81 (1H, s, H-1), 7.29 (1H, d, J = 8.4 Hz, H-12), 7.53 (1H, d, J = 8.4 Hz, H-11); 13C-NMR δ: 31.8 (C-5), 39.5 (C-6), 57.5 (10-OCH3), 62.8 (9-OCH3), 92.2 (-OCH2O-), 103.9 (C-13a), 109.6 (C-12), 110.7 (C-11), 118.8 (C-4), 121.8 (C-1), 124.5 (C-12a), 132.6 (C-8a), 135.4 (C-1a), 138.1 (C-4a), 147.9 (C-2), 148.9 (C-3), 153.4 (C-10), 156.2 (C-9), 168.6 (C-8), 203.9 (C-13).

8,13-Dioxo-14-methoxycanadine (13): faint yellow powder; HRESIMS m/z 397.1158 [M]+ (calcd for C21H19NO7 397.1162); 1H-NMR δ: 2.78–2.80 (2H, m, H-5), 3.16 (3H, s, 14-OCH3), 3.21 (1H, m, H-6α), 3.92 (3H, s, 9-OCH3), 3.98 (3H, s, 10-OCH3), 4.93 (1H, m, H-6β), 5.98 (2H, s, -OCH2O-), 6.73 (1H, s, H-4), 6.87 (1H, s, H-1), 7.37 (1H, d, J = 9.0 Hz, H-12 ), 7.74 (1H, d, J = 9.0 Hz, H-11).

Corydaline (14): faint yellow powder; HRESIMS m/z 370.2011 [M+H]+ (calcd for C22H28NO4 370.2018); 1H-NMR δ: 0.95 (3H, d, J = 7.2 Hz, CH3), 2.60 (2H, m, H-5), 3.11 (2H, m, H-6), 3.23 (1H, m, H-13), 3.52 (1H, d, J = 15.6 Hz, H-8α), 3.71 (1H, d, J = 2.4 Hz, H-13a), 3.89 (12H, m, OCH3 × 4), 4.16 (1H, d, J =15.6 Hz, H-8β), 6.62 (1H, s, H-4), 6.67 (1H, s, H-1), 6.82 (1H, d, J = 9.0 Hz, H-11), 6.90 (1H, d, J = 9.0 Hz, H-12); 13C-NMR δ: 18.2 (13-CH3), 29.2 (C-5), 38.2 (C-13), 51.3 (C-6), 55.5 (-OCH3), 55.6 (-OCH3), 56.0 (-OCH3), 60.0 (-OCH3), 63.0 (C-13a), 108.7 (C-1), 110.8 (C-4), 111.1 (C-11), 123.8 (C-12), 128.4 (C-4a, C-8a, C-1a), 134.8 (C-12a), 146.0 (C-10), 147.1 (C-2), 147.5 (C-3), 145.0 (C-9).

Tetrahydrothalifendine (15): faint yellow powder; HRESIMS m/z 326.1395 [M+H]+ (calcd for C19H20NO4 326.1392); 1H-NMR δ: 2.68 (2H, m, H-5), 2.84 (1H, dd, J13β, 13a = 12.6 Hz, J13β, 13a = 15.6 Hz, H-13a), 3.13 (1H, dd, J13α, 13a = 3.6 Hz, J13α, 13β = 15.6 Hz, H-13β), 3.32 (2H, m, H-6), 3.53 (1H, d, J = 15.6 Hz, H-8α), 3.57(1H, dd, J13α, 13β = 12.6 Hz, J13α, 13a = 3.6 Hz, H-13a), 3.91(3H, s, OCH3), 4.15(1H, d, J = 15.6 Hz, H-8β), 5.96 (2H, s, -OCH2O-), 6.63 (1H, s, H-4), 6.67 (1H, s, H-1), 6.62 (1H, d, J = 9.0 Hz, H-11 ), 6.90 (1H, d, J = 9.0 Hz, H-12 ); 13C-NMR δ: 29.2 (C-5), 36.2 (C-13), 51.5 (C-6), 53.0 (C-8), 59.0 (C-13a), 55.1 (-OCH3), 101.3 (-OCH2O-),106.7 (C-1), 110.8 (C-4), 111.3 (C-11), 121.7 (C-12), 125.9 (C-8a), 127.1 (C-12a), 127.8 (C-4a), 131.0 (C-1a), 143.0 (C-10), 144.1 (C-2), 144.0 (C-3), 145.0 (C-9).

3.4. Cytotoxicity Testing

The cytotoxicity of the compounds was determined using the colorimetric methythiazoletetrazolium (MTT) assay with taxol as the positive control (IC50 value 0.15 µM). The human stomach cancer cell line SGC 7901 in logarithmic phase were seeded in 96 well flat bottom microtitre plates at a density of 1 × 104 cells per well. cells were washed and maintained with different concentrations of drug, 10 µL MTT was added to the culture medium to a final concentration of 0.5 mg/mL and incubated at 37 °C for 4 h. Formazan crystals dissolved in 100 µL DMSO was added and 10 min later the absorbance of the solution was measured at a wavelength of 570 nm. All assays were carried out in triplicate.

4. Conclusions

From the chemical investigation of stems of A. gusanlung, fifteen protoberberine alkaloids including a new one, named gusanlung E (1), were isolated and identified. Gusanlung E (1) showed weak
cytotoxicity against cancer cell line SGC 7901. These analogues should be studied in more advanced models to establish in vivo efficacy.

Supplementary Materials

Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/9/13332/s1.

Acknowledgments

This work was supported by the Chinese National S&T Special Project on Major New Drug Innovation (2011ZX09307-002-01), Program for Innovative Research Team in IMPLAD (IT1305), Outstanding Young Talent Project of Scientific Research Plan of Education Department of Hubei Province (Q20131309) and Science Foundation of China Three Gorges University (KJ2011B050).

Author Contributions

Y.L.L. and Z.Z.M. designed the research; Y.L.L., L.R.T., A.Y.B., L.W. and D.Z.S. performed the experimental work; Y.L.L. wrote the manuscript. All authors discussed, edited and approved the final version.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Chinese Pharmacopoeia; People’s Medical Publishing House: Beijing, China, 1977; p. 521.
2. Garcia, L.M.; Jewers, K.; Manchanda, A.H.; Martinod, P.; Nabney, J.; Robinson, F.V. The alkaloids of Arcangelisia Loureiri and Coscinium Wallichianum. Phytochemistry 1970, 9, 663–664.
3. Zhang, J.S.; Chen, Z.L. Two new 8-oxotetrahydroprotoberberine alkaloids, gusanlung A and B, from Arcangelisia gusanlung. Planta Med. 1991, 57, 457–459.
4. Zhang, J.S.; Men-Olivier, L.L.; Massiot, G. Isoquinoline alkaloids from Arcangelisia Gusanlung. Phytochemistry 1995, 39, 439–442.
5. Yu, L.L.; Hu, W.C.; Ding, G.; Li, R.T.; Wei, J.H.; Zou, Z.M.; Wang, M. Gusanlungionosides A–D, potential tyrosinase inhibitors from Arcangelisia gusanlung. J. Nat. Prod. 2011, 74, 1009–1014.
6. Gao, J.M.; Kamnaing, P.; Kiyota, T.; Watchueng, J.; Kubo, T.; Jarussophon, S.; Konishi, Y. One-step purification of palmatine and its derivative dl-tetrahydropalmatine from Enantia chlorantha using high-performance displacement chromatography. J. Chromatogr. A 2008, 1208, 47–53.
7. Gao, J.M.; Liu, W.T.; Li, M.L.; Liu, H.W.; Zhang, X.C.; Li, Z.X. Preparation and structural elucidation of (−)-tetrahydroberberine-(+)2,3-di(p-toluyl) tartaric acid complex. J. Mol. Struct. 2008, 892, 466–469.
8. Lenka, G.; Jiri, D.; Radek, M. Quaternary protoberberine alkaloids. Phytochemistry 2007, 68, 150–175.
9. Blanchfield, J.T.; Sands, D.P.A.; Kennard, C.H.L.; Byriel, K.A.; Kitching, W. Characterisation of alkaloids from some Australian Stephania (Menispermaceae) species. Phytochemistry 2003, 63, 711–720.
10. Guo, Y.Y.; Lin, L.B.; Fu, X.W.; Kojima, K.; Ogihara, Y. Studies on alkaloids from *Tinospora hainanensis*. *Acta Pharmacol. Sin.* **1999**, *34*, 690–693.

11. Inqkaninan, K.; Phenqpa, P.; Yuenyongsawad, S.; Khorana, N. Acetylcholinesterase inhibitors from *Stephania venosa* tuber. *J. Pharm. Pharmacol.* **2006**, *58*, 695–700.

12. Takao, N.; Iwasa, K.; Kamiguchi, M.; Sugiuara, M. Studies on the alkaloids of papaveraceous plants. XXIX. Conformational analysis of tetrahydroprotobererines by carbon-13 magnetic resonance spectroscopy. *Chem. Pharm. Bull.* **1977**, *25*, 1426–1435.

13. Takao, T.; Yuko, S.; Naotaka, N.; Hidekazu, N. Quaternary isoquinoline alkaloids from *Stephania cepharantha*. *Chem. Pharm. Bull.* **2000**, *48*, 370–373.

14. Tao, J.H.; Zhang, X.Q.; Ye, W.C.; Zhao, S.X. Chemical constituents from *Corydalis humosa*. *J. Chin. Med. Mat.* **2005**, *28*, 556–557.

15. Su, Y.F.; Lan, H.Y.; Zhang, Z.X.; Guo, C.Y.; Guo, D. Chemical constituents of *Semia quilegia adoxoides*. *Chin. Tradit. Herbal Drugs* **2006**, *37*, 27–29.

16. Raouf, A.; Jinwoong, K.; Christopher, W.W.; A. Douglas, K. Unambiguous carbon-13 NMR assignments of some biologically active protoberberine alkaloids. *Hererocycles* **1989**, *29*, 2257–2260.

17. Amarendra, P.; Craig, T.M.; Alan, J.F.; Hélène, G.; Maurice, S.; Bamrung, T.; Kakaya, P. The protoberberine alkaloids of *Stephania suberosa*. *Phytochemistry* **1987**, *26*, 547–549.

18. Min, Y.D.; Yang, M.C.; Lee, K.H.; Kim, K.R.; Choi, S.U.; Lee, K.R. Protoberberine alkaloids and their reversal activity of P-gp expressed multidrug resistance (MDM) from the rhizome of *Coptis japonica* Makino. *Arch. Pharm. Res.* **2006**, *29*, 757–761.

19. Qu, Y.; Liu, M.; Wu, Z.H.; Gao, H.Y.; Sun, B.H.; Su, Q.J.; Wu, L.J. 2, 3, 9, 10-Tetraoxygenated Protoberberine Alkaloids from *Corydalis yanhusuo* W. T. Wang. *Asian J. Tradi. Med.* **2007**, *2*, 61–65.

20. Yu, R.; Ye, Q.; Chen, B.; Zhang, G.L. Chemical study on *Mitrephora mainga yi*. *Nat. Prod. Res. Deve* **2003**, *15*, 212–215.

21. Cheng, C.M.; Dai, Y.; Huang, X.Z.; Zhu, Y.; Dai, J.H.; Liu, X.F.; Wang, J. Chemical constituents from roots of *Tinospora sagittata var. yunnanensis*. *Chin. Tradit. Herbal Drugs* **2010**, *41*, 689–692.

22. Moniot, J.L.; Hindenlang, D.M.; Shamma, M. Chemistry of 8, 13-dioxoberbines. *J. Org. Chem.* **1979**, *44*, 4343–4346.

23. Valencia, E.; Weiss, I.; Firdous, S.; Freyer, A.J.; Shamma, M. The isoidolobenzazepine alkaloids. *Tetrahedron* **1984**, *40*, 3957–3962.

24. Xu, X.H.; Wang, Z.T.; Yu, G.D.; Ruan, B.F.; Li, J. Alkaloids from *Rhizoma corydalis*. *J. Chin. Pharm. Univ.* **2002**, *33*, 483–486.

25. Li, J.C.; Dong, X.H.; Deng, J.W.; Dai, Y.; Zhang, J.S.; Li, G.P. Studies on the alkaloids from roots of *Cordalis impatiens*. *J. Chin. Med. Mat.* **2010**, *33*, 210–213.

Sample Availability: Samples of the compounds are not available from the authors because bioactivity tests of those compounds are going on.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).